4D Molecular Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $3.80M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $3.00M | $-1.01 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | $15.00K | $-0.98 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $14.00K | $-0.86 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 28, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | $3.00K | $-0.79 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
Press releases
Announcements 4D Molecular Therapeutics filed with the SEC
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports Full Year 2025 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports Full Year 2024 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
Intravitreal 4D-150 DME Clinical Trial: Part 1 Interim 32-week Results January 10, 2025 EXHIBIT 99.1
Results of operations · Other events · EX-99.1 to Form 8-K
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
4D Molecular Therapeutics Reports Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K